Coagulation hemostasis disorders and elevated lipoprotein (a) levels in patients with arterial hypertension and multifocal atherosclerosis
Open Access
- 30 October 2024
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 46-52
Abstract
Introduction. Hemostatic disorders may act as additional risk factors in patients with arterial hypertension (AH) and multifocal atherosclerotic lesion (MFAL). Elevated lipoprotein (a) (Lp(a)) levels may exacerbate procoagulant shifts.Aim. To identify disorders in the coagulation link of hemostasis in patients with AH and MFAL, depending on the level of Lp(a).Materials and methods. The study included 219 patients with hypertension and MFAL, median age 59 (53; 66) years, of which 110 patients with stage I–II controlled hypertension (group 1) and 109 patients with stage III controlled hypertension with a history of ischemic stroke. Depending on the level of Lp(a), patients in each group were divided into 2 subgroups with Lp(a) levels < 50 mg/dl and with Lp(a) levels above 50 mg/dl. Patients of both groups received antihypertensive, lipid-lowering, antiplatelet therapy and had comparable values of blood pressure and lipid spectrum.Results. In group 2 patients, procoagulant shifts were significantly more often recorded, despite the constant use of antiplatelet therapy. Violations of hemostasis parameters depending on the level of Lp(a) were observed in subgroups 1b and 2b. According to the results of multiple a posteriori comparisons, the most significant hypercoagulation changes were observed in patients with stroke, as well as with Lp(a) levels > 50 mg/dl.Conclusions. Thus, in some patients with hypertension and MFAL, despite taking antihypertensive, lipid-lowering and antiplatelet therapy, coagulation hemostasis disorders may occur. Elevated Lp(a) levels are combined with more pronounced hemostatic disorders, especially in the presence of a previous stroke. Intensification of antithrombotic therapy may be considered in such patients to prevent cardiovascular complications.Keywords
This publication has 30 references indexed in Scilit:
- Beyond fibrinolysis: The confounding role of Lp(a) in thrombosisAtherosclerosis, 2022
- The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic StrokeTranslational Stroke Research, 2020
- Tissue factor in atherosclerosis and atherothrombosisAtherosclerosis, 2020
- Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography studyIJC Heart & Vasculature, 2019
- Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarctionIndian Heart Journal, 2019
- Lipoprotein(a): A missing culprit in the management of athero‐thrombosis?Journal of Cellular Physiology, 2017
- A Test in Context: Lipoprotein(a)JACC, 2017
- Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysisAtherosclerosis, 2015
- Association between inflammation and hemostatic markers in atherothrombotic strokeThrombosis Research, 2003
- Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.Proceedings of the National Academy of Sciences of the United States of America, 1989